A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer Read more about A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
Study of XB010 in Subjects With Solid Tumors Read more about Study of XB010 in Subjects With Solid Tumors
Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer Read more about Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 Read more about Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer Read more about Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
E-Mindfulness Approaches for Living After Breast Cancer Read more about E-Mindfulness Approaches for Living After Breast Cancer
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab Read more about ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Comprehensive Outcomes for After Cancer Health Read more about Comprehensive Outcomes for After Cancer Health
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd Read more about TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd